3-(3-丁炔-1-基)吡啶 | 147918-36-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(3-丁炔-1-基)吡啶
• 英文名称: 3-(but-3-yn-1-yl)pyridine
• 英文别名: 3-but-3-yn-1-ylpyridine；4-(3-Pyridil)-1-butin；3-but-3-ynylpyridine
• CAS: 147918-36-3
• 化学式: C₉H₉N
• 分子量: 131.177
• InChiKey: WUKPYBAXHUSNSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(3-丁炔-1-基)吡啶 在 palladium on activated charcoal 吡啶 、 六甲基磷酰三胺 、 正丁基锂 、 氢气 、 对甲苯磺酸 作用下， 以 甲醇 、 环己烷 、 苯 为溶剂， -45.0~20.0 ℃ 、100.0 kPa 条件下， 反应 6.92h， 生成 <(Z)-14-(3-Pyridyl)-11-tetradecenyl>-p-toluolsulfonat
  参考文献：
  名称：

  Teubner, Achim; Gerlach, Hans, Liebigs Annalen der Chemie, 1993, # 2, p. 161 - 166

  摘要：

  DOI：
• 作为产物：
  描述：

  3-吡啶丙醇 在 草酰氯 、 potassium carbonate 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 3-(3-丁炔-1-基)吡啶
  参考文献：
  名称：

  Amphimedosides A–C: Synthesis, Chemoselective Glycosylation, And Biological Evaluation

  摘要：

  The amphimedosides, discovered in 2006, are the first examples of naturally occurring glycosylated alkoxyamines. We report syntheses of amphimedosides A-C that feature a stereoselective oxyamine neoglycosylation and found that these alkaloids display modest cytotoxicity toward seven diverse human cancer cell lines, exhibiting IC50 values ranging from 3.0 mu M to greater than 100 mu M.

  DOI：

  10.1021/jo302640y

文献信息

• Decarboxylative Alkynylation
  作者：Joel M. Smith、Tian Qin、Rohan R. Merchant、Jacob T. Edwards、Lara R. Malins、Zhiqing Liu、Guanda Che、Zichao Shen、Scott A. Shaw、Martin D. Eastgate、Phil S. Baran

  DOI：10.1002/anie.201705107

  日期：2017.9.18

  The development of a new decarboxylative cross‐coupling method that affords terminal and substituted alkynes from various carboxylic acids is described using both nickel‐ and iron‐based catalysts. The use of N‐hydroxytetrachlorophthalimide (TCNHPI) esters is crucial to the success of the transformation, and the reaction is amenable to in situ carboxylic acid activation. Additionally, an inexpensive

  描述了使用镍基和铁基催化剂的新型脱羧交叉偶联方法的开发，该方法可从各种羧酸中获得末端炔烃和取代炔烃。使用N-羟基四氯邻苯二甲酰亚胺（TCNHPI）酯对于成功转化至关重要，并且该反应适合原位羧酸活化。此外，在这种正式的同源过程中，使用了一种廉价的，可商购的炔烃来源，作为其他公认的炔烃合成的替代品。该反应操作简单，适用范围广，同时为先前报道的合成中间体提供了简洁，可扩展的途径。
• PYRIDINE-THIAZOLE-OXIME AND PYRIDINE-OXAZOLE-OXIME DERIVATIVES AS REACTIVATORS OF ORGANOPHOSPHOROUS NERVE AGENT (OPNA)-INHIBITED HUMAN ACETYLCHOLINESTERASE FOR THE TREATMENT OF NERVOUS AND/OR RESPIRATORY FAILURE AFTER INTOXICATION WITH OPNA
  申请人：Centre National de la Recherche Scientifique

  公开号：EP3915983A1

  公开（公告）日：2021-12-01

  The present invention relates to a compound of formula (I): wherein X is O or S; Y is -CH2-CH2-, -C=C- or -CH=CH-; Z is -CH2-; n is an integer from 0 to 4; and R is an alkyl group, an aryl, a heteroaryl, a cycloalkyl, a heterocyclyl, a biomolecule, a fluorescent probe, or a group -N(R1 )(R2); wherein R1 and R2 are each independently H, an alkyl group, an aryl, a heteroaryl or a cycloalkyl. It also relates to a pharmaceutical composition comprising at least one compound of formula (I) and at least one pharmaceutically acceptable support. Finally, it relates to the use of such a compound as a medicine, preferably in the treatment of a nervous and/or respiratory failure due to intoxication with at least one organo-phosphorous nerve agent (OPNA); in the treatment of neurological diseases such as Alzheimer's disease; and/or in the treatment of cancer. The compounds act as reactivators of OPNA-inhibited hAChE (human acetylcholinesterase). The present description discloses the syntheses of exemplary compounds as well as experimental data on the in vitro reactivation of human acetylcholinesterase (hAChE) by the compounds of the invention (e.g. pages 28 to 56; examples 1 and 2; compounds; tables 1 to 3). Exemplary compounds are e.g.: or

  本发明涉及一种具有如下式（I）的化合物：其中X为O或S；Y为-CH2-CH2-，-C=C-或-CH=CH-；Z为-CH2-；n为0至4之间的整数；R为烷基，芳基，杂芳基，环烷基，杂环烷基，生物分子，荧光探针或-N（R1）（R2）基团；其中R1和R2分别独立地为H，烷基，芳基，杂芳基或环烷基。还涉及包含至少一种如上式（I）化合物和至少一种药学上可接受的载体的药物组合物。最后，涉及将这种化合物用作药物，优选用于治疗由至少一种有机磷神经毒剂（OPNA）中毒引起的神经和/或呼吸衰竭；治疗像阿尔茨海默病这样的神经疾病；和/或治疗癌症。这些化合物作为OPNA抑制的hAChE（人乙酰胆碱酯酶）的再激活剂。本说明披露了示例化合物的合成以及通过体外实验数据来展示本发明化合物对人乙酰胆碱酯酶（hAChE）的再激活（例如，第28至56页；示例1和2；化合物；表1至3）。示例化合物包括：【这里可能包含一些化合物的图示或名称】
• DIAZINOXIMES SCAFFOLDS
  申请人：Centre national de la recherche scientifique

  公开号：EP3967686A1

  公开（公告）日：2022-03-16

  The present invention relates to a compound of formula (I). It also relates to a pharmaceutical composition comprising at least one compound of formula (I) and at least one pharmaceutically acceptable support. Finally, it relates to the use of such a compound as a medicine, preferably in the treatment of a nervous and/or respiratory failure due to intoxication with at least one organophosphorous nerve agent by reactivation of AChE; in the treatment of neurological diseases such as Alzheimer's disease; and/or in the treatment of cancer.

  本发明涉及一种化合物，其化学式为(I)。它还涉及一种含有至少一种化学式(I)化合物和至少一种药学上可接受的载体的药物组合物。最后，它涉及将这种化合物用作药物，优选用于治疗由至少一种有机磷神经毒剂中毒引起的神经和/或呼吸衰竭，通过重新激活AChE；治疗像阿尔茨海默病这样的神经系统疾病；和/或治疗癌症。
• Optimisation of ITK inhibitors through successive iterative design cycles
  作者：Matthias Herdemann、Alexander Weber、Jérôme Jonveaux、Frank Schwoebel、Michael Stoeck、Isabelle Heit

  DOI：10.1016/j.bmcl.2011.01.035

  日期：2011.3

  Based on a hit cluster of compounds inhibiting interleukin-2 inducible T-cell kinase (ITK) in the submicromolar range a series of ITK inhibitor libraries were synthesized. Through iterative design cycles including kinase crystal structure information, indolylindazole libraries were identified which showed low nanomolar activity in enzymatic and cellular assays. The potential of these novel lead series was confirmed through in vivo tests in an anti-CD3-IL2 mouse model. The intravenous administration of highly potent ITK inhibitor 11o resulted in dose-dependent, efficient suppression of IL-2. (C) 2011 Elsevier Ltd. All rights reserved.
• FERMENTATION PROCESS FOR EPOTHILONES
  申请人：Kosan Biosciences, Inc.

  公开号：EP1303615A2

  公开（公告）日：2003-04-23